{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Atanasova VS"],"funding":["(H.D.) and internal institutional funding (Inst. of Medical Genetics, Medical Uni-versity of Vienna)","the Medical University of Vienna","the Niederösterreichische Forschungs und Bildungsges.m.bH.","Austrian Academy of Sciences","MiB"],"pagination":["1668"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9863259"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(2)"],"pubmed_abstract":["Colorectal cancer (CRC) is the second deadliest cancer in the world. Besides APC and p53 alterations, the PI3K/AKT/MTOR and MAPK pathway are most commonly mutated in CRC. So far, no treatment options targeting these pathways are available in routine clinics for CRC patients. We systematically analyzed the response of CRC cells to the combination of small molecular inhibitors targeting the PI3K and MAPK pathways. We used CRC cells in 2D, 3D spheroid, collagen gel cultures and freshly isolated organoids for drug response studies. Readout for drug response was spheroid or organoid growth, spheroid outgrowth, metabolic activity, Western blotting and immunofluorescence. We found profound tumor cell destruction under treatment with a combination of Torin 1 (inhibiting mTOR), MK2206 (targeting AK"],"journal":["International journal of molecular sciences"],"pubmed_title":["Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition."],"pmcid":["PMC9863259"],"funding_grant_id":["the WWTF Grant #LS20-042 "CheckMate-CRC"","the Niederösterreichische Forschungs und Bildungsges.m.bH.","NFB, LSC18017","DOC fellowship","CCC research grant (Initiative Krebsforschung)"],"pubmed_authors":["Flandorfer J","Hengstschlager M","Strobl M","Dolznig H","Unterleuthner D","Bergmann M","Riedl A","Weindorfer C","Neuhold P","Stang S","Atanasova VS"],"additional_accession":[]},"is_claimable":false,"name":"Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition.","description":"Colorectal cancer (CRC) is the second deadliest cancer in the world. Besides APC and p53 alterations, the PI3K/AKT/MTOR and MAPK pathway are most commonly mutated in CRC. So far, no treatment options targeting these pathways are available in routine clinics for CRC patients. We systematically analyzed the response of CRC cells to the combination of small molecular inhibitors targeting the PI3K and MAPK pathways. We used CRC cells in 2D, 3D spheroid, collagen gel cultures and freshly isolated organoids for drug response studies. Readout for drug response was spheroid or organoid growth, spheroid outgrowth, metabolic activity, Western blotting and immunofluorescence. We found profound tumor cell destruction under treatment with a combination of Torin 1 (inhibiting mTOR), MK2206 (targeting AK","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-04T14:27:03.473Z","creation":"2025-04-04T14:27:03.473Z"},"accession":"S-EPMC9863259","cross_references":{"pubmed":["36675180"],"doi":["10.3390/ijms24021668"]}}